The school has been selected as one of the United Kingdom sites for phase III of the University of Oxford's COVID-19 vaccine clinical trial.
Speaking about the recent Reuters survey, Dr. William Schaffner, an infectious disease and vaccine expert at Vanderbilt University Medical Centre in Nashville said: "It's a little lower than I thought it would be with all the attention to COVID-19".
Fox News has reached out to Oxford University and the Medicines and Healthcare products Regulatory Agency with a request for comment.
"The next study will enroll up to 10,260 adults and children and will involve a number of partner institutions across the country", they explained in the statement. Stage 3 of the trials will include studying the vaccine's performance in bodies of a large count of adults, aged 18 years and above.
Building on the group's success in recruiting volunteers to numerous studies mostly focused on respiratory infection predominately pneumonia and vaccines, communications have been sent out to all of the NHS Trusts within Merseyside as well as to CCGs, GPs and care homes asking for volunteers.
To assess whether the vaccine works, Oxford's statisticians will compare the number of infections in the control group to the number of infections in the vaccinated group. How do you address what Mr. Blankfein is saying today and what others have said in the past days, that's it's just time to open this country up and protect the most vulnerable. "How quickly we reach the numbers required will depend on the levels of virus transmission in the community".
The data will then be shared among the +5 companies that will take part.
Earlier this week, drugmaker AstraZeneca said it had secured its first agreements for 400 million doses of the Oxford-developed vaccine, bolstered by a $1 billion investment from a US government agency, for the development, production and delivery of the vaccine, starting in the fall.